BAB VII SIMPULAN DAN SARAN
7.2 Saran
1. Penelitian ini dapat dijadikan dasar pemilihan obat anestesi induksi, terutama pada pasien dengan infeksi penyerta atau yang berisiko terjadi SIRS maupun sepsis.
2. Perlu dilakukan penelitian lebih lanjut terhadap komponen inflamasi lainnya sehingga diharapkan dapat mempertegas proses peningkatan kadar leukosit.
DAFTAR PUSTAKA
1. Balk RA. Severe Sepsis and Septic Shock, Definition, Epidemiology and Clinical Manifestation. Crit Care Clin, 2000;16 (2)179-92.
2. Delinger RP. Surviving Sepsis Compaign Guidelines for Management of Severe Sepsis and septic Shock. Crit Care Med,2004; 32: 858-873.
3. Mohammed Azam Danish. Propofol in Dr Azam’s Notes in Anesthesiology. 2nd Ed, Philadelphia : Lippincott; 2010, 27-346.
4. Trapani G, Altomare C, Liso G, Sanna E, Biggio G. Propofol in anesthesia. Mechanism of action, structure-activity relationships and drug delivery. Dipartimento Farmaco-Chimico, Facolta di Farmacia, Universita degli Studi di Bari, Via Orabona 4, Bari, Italie. 2000; 7: 249-71. Available from : [on line] : URL.http//.www.Italy.trapani@farmchim.uniba.it.
5. Stoelting RK, Hillier SC, Pharmacology & Physiology in Anesthetic Practice, 4th edition,2006;155-178.
6. Crosby ET. The unanticipated difficult airway with recommendations ormanagement. Can J Anesthesia 1998; 45: 757-76. Published: EmergencyMedicine Alert ; November 2005.
7. Taha S, Siddik S, Alameddine M. Propofol is superior to tiopental for intubation without muscle relaxant.Can J Anesthesia 2005; 52: 249-53. 8. Elvan MD, Gulden U MD. Propofol Not thiopenton or etomidate with
remifentanil provides adequate intubating condition the absence of neuromuscular blockade. Can J Anesthesia 2003; 50: 108-15.
9. Bryan A, Oscar D, Guillamondegui, Sloan B, Fleming, Robert O, et al. Increased risk of adrenal insufficiency following etomidate exposure in critically injured patients. Arch Surg 2008 ; 143(1).
10. Brinker M, Anita CS, Hazelzet J, Frank H, Hop WCJ, Joosten K, et al. One single dose of etomidate negatively influences adrenocortical performance for at least 24 hour in children with meningococcal sepsis. Intensive Care Med 2008; 34: 163 – 8.
11. Murray H, Marik PE. Etomidate for endotracheal intubation in sepsis. Chest Journal 2005 ; 127 : 707 – 9.
12. Jackson WL. Should we use etomidate as an induction agent for endotracheal intubation in patients with septic shock?. A critical appraisal. Chest Journal 2005 ; 127 : 1031 – 8.
13. Morris C, McAllister C. Etomidate for emergency anaesthesia : mad, bad and dangerous to know?. J Anaesthesia 2005 ; 60 : 737 – 40.
14. Hildreth AN, Mejia VA, Maxwell RA, Smith PW, Dart BW, Barker DE. Adrenal supression following a single dose of etomidate for rapid sequence induction : A prospective randomized study. J Trauma 2008 ; 65 (3) : 573–9. 15. American College of Chest Physicians/Society of Critical Care Medicine
Consensus Conference: Definitions for Sepsis and Organ Failure and Guidelines for The Use of InnovativeTherapies in Sepsis. Critical Care Medicine, 1992. Vol 20 no 6.
16. Levy Mm, Fink MP, Marshall JC, et al. 2001/SCCM/ESICM/ACCP/ ATS/SIS/International Sepsis Definitions Conference. Crit Care Med, 2003; 31:1250-1256.
17. Baptiste E. Cellular Mechanisms in Sepsis. Journal of Intensive Care Medicine 2007 ; 22 : 63-72.
18. Guntur HA. SIRS dan Sepsis ( Imunologi, Diagnosis, Penatalaksanaan). Sebelas Maret University Press. Edisi pertama 2006.
19. Balci C, Sungurtekin H, Gurses E, et al. Usefulness of Procalcitonin for Diagnosis of Sepsis in The Intensive Care Unit. Critical Care, 2003, 7 : 85-90.
20. Ismanoe G. The Role of Cytokine in The Pathobiology of Sepsis. National Symposium : The 2nd Indonesian Sepsis Forum. Surakarta 2008.
21. AV.Hoffbrand, JE.Pettit, PAH.Moss. Kapita Selekta Hematologi. Jakarta : Penerbit Buku Kedokteran EGC. 2005.
22. O'Connor E, Venkatesh B, lipman J, et al. Procalcitonin in Critical Illness. Critical Care and Resuscitation. 2001; 3: 236-243.
23. Marik PE: Propofol: An immunomodulating agent. Pharmacotherapy 2005;25:28S–33S.
24. Ohmizo H, Obara S, Iwama H. Mechanism of injection pain with long and long-medium chain triglyceride emul-sive propofol. Can J Anaesth 2005;52(6):595–9.
25. Lopez AF, Cubells CL, Garcia JJ, Pou JF. Procalcitonin In Pediatric Emergency Departments for the Early Diagnosis of Invasive Bacterial Infections in Febrile Infants: Results of a Multicenter Study and Utility of a Rapid Qualitative Test for This Marker. Pediatric Infectious Disease Journal, 2003; 22: 895-903.
26. Reves JG, Glass PSA, Lubarsky DA, et al. “Intravenous Nonopioid Anesthetics.” Miller’s Anesthesia, Sixth Edition. Churchill Livingstone: Philadelphia. 2005
27. Shiga T. Predicting difficult intubation in apparently normal patients.Anesthesiology, 2005; 103: 429-37
28. Hammer C, Hobel G, Hamme S, et al. Diagnosis and Monitoring of Inflammatory Events in Transplant Patients.In:Trull Ak, Demers LM, Holt DW, et al. Biomarkers of Disease An Evidence-Based Approach Cambridge University Press, Cambridge United Kingdom. 2002 : 474-481. 29. Evers AS. Inhalational anesthetics. In: Evers AS, Maze M, eds. Anesthetic
Pharmacology, Physiologic Principles and Clinical Practice. Pennsylvania: Churchill Livingstone, 2004: 369–93.
30. Mokart D,Merlin M, Saninni A, Brun J.P, Delpero J.R, Houvenaeghel G, Mourtardir V, Blache J.L. Procalcitonin, interleukin 6 and systemic inflamatory respone syndrome (SIRS): early markers of post operative sepsis after major surgery. British journal of anaesthesia 2005; 94(6):767-773
31. Karzai W, Oberhoffer M, MeierHellmann A, Reinhart K.Procalcitonin – a new indicator of the systemic response to severe infection. Infection 1997; 25: 329–334.
32. Stoelting, Robert K, Hillier, Simon C. Nonbarbiturate Intravenous Anesthetic Drugs in Handbook of Pharmacology and Physiology in Anesthetic Practice. 2nd Ed, Philadelphia : Lippincott; 2006, 156-63.
33. Bozeman WP, Kleiner DM, Huggett V. A comparison of rapid-sequence intubation and etomidate-only intubation in the prehospital air medical setting. Prehosp Emerg Care. 2006; 10(1): 8-13.
34. Zuckerbraun NS, Pitetti RD, Herr SM, et al. Use of etomidate as an induction agent or rapid sequence intubation in a pediatric emergency department. Acad Emerg Med. 006; 13(6):02-9.
35. Miller B, Berker KL. Procalcitonin: How a Hormone Became a Marker and Mediator of Sepsis. Swiss Med WKLY.2001;131 : 595-602
36. Wagner RL, White PF, Kan PB, Rosenthal MH, Feldman D. Inhibitionof adrenal steroidgenesis by the anesthetic etomidate.NEJM 1984;310:1415-21. 37. Suyatno, Emir T.P. Kanker payudara dalam Bedah onkologi diagnostik dan
terapi, Sagung seto 2009; 35-58.
38. Dosow V.V, Haas A, Kastrup M, Geyer T, Spies D. Influence of remifentanil versus fentanyl analgesia on the perioperative course of plasma procalcitonin levels in patients undergoing cardiac surgery. American society of anesthesiologists. Annual meeting abstrcts; 2010.
39. Susanne C, Peter F, Joerg M, Klaus P. Effect of sevoflirane and propofol on procalcitonin and C-reactive protein concentration in patients undergoing off-pum coronary artery bypass graft surgery. American society of anesthesiologists. Annual meeting abstrcts; 2002.
LAMPIRAN
Obat Umur TB BB Lama Op. Hb pre Leu pre Leu post1 Leu post2
Propofol 40 156 56 130 14,9 8600 8700 9600 Propofol 21 148 60 120 13,4 6500 7000 8300 Propofol 37 152 48 140 12,3 5300 7100 8100 Propofol 41 155 45 130 14,3 5600 14000 14500 Propofol 27 153 47 120 13,2 4500 5000 6000 Propofol 61 150 53 150 10,3 4800 7900 11500 Propofol 56 153 65 140 12,6 8000 10700 14000 Propofol 58 155 54 145 12,3 7400 11000 13500 Pentothal 40 154 62 130 14 5400 5900 6000 Pentothal 38 157 65 90 13,1 5700 6000 6300 Pentothal 43 159 59 120 12,3 6900 6900 6800 Pentothal 57 160 60 120 12,3 6500 7600 9800 Pentothal 23 162 58 150 10,5 5900 6200 6900 Pentothal 34 156 55 160 10,7 7800 8000 7900 Pentothal 66 157 38 75 10,2 4600 5500 5400 Pentothal 29 153 64 90 11,5 8700 8800 6700 Etomidate 56 155 56 100 13,2 4300 4600 6000 Etomidate 47 165 54 90 11,2 5000 5500 6500 Etomidate 45 156 65 160 12,3 4500 5100 5300 Etomidate 37 156 46 120 13,1 4100 4500 7000 Etomidate 47 145 48 145 11,6 3400 4300 4500 Etomidate 49 153 54 130 10,6 4200 4200 4500 Etomidate 32 156 52 120 11,7 4500 5100 5500 Etomidate 46 157 51 130 13 6700 7000 7500
Tests of Normality
Jenis.Obat Kolmogorov-Smirnova Shapiro-Wilk
Statistic Df Sig. Statistic df Sig.
BB Propofol .165 8 .200* .958 8 .789 Pentothal .267 8 .096 .774 8 .015 Etomidate .198 8 .200* .921 8 .438 TB Propofol .172 8 .200* .937 8 .584 Pentothal .158 8 .200* .975 8 .934 Etomidate .258 8 .124 .874 8 .164 Umur Propofol .194 8 .200* .928 8 .502 Pentothal .201 8 .200* .947 8 .682 Etomidate .257 8 .129 .925 8 .474 Lama.Operasi Propofol .193 8 .200* .923 8 .459 Pentothal .189 8 .200* .944 8 .653 Etomidate .173 8 .200* .971 8 .909 Hb.pre Propofol .207 8 .200* .957 8 .777 Pentothal .174 8 .200* .945 8 .659 Etomidate .203 8 .200* .922 8 .444 Leu.pre Propofol .185 8 .200* .933 8 .544 Pentothal .156 8 .200* .973 8 .918 Etomidate .286 8 .053 .842 8 .080 Leu.post1 Propofol .156 8 .200* .961 8 .822 Pentothal .215 8 .200* .929 8 .511 Etomidate .223 8 .200* .840 8 .075 Leu.post2 Propofol .189 8 .200* .925 8 .475 Pentothal .272 8 .083 .887 8 .219 Etomidate .139 8 .200* .945 8 .662
*. This is a lower bound of the true significance. a. Lilliefors Significance Correction
Frequencies
Statistics
BB TB Umur Lama.Operasi Hb.pre Leu.pre Leu.post1 Leu.post2
N Valid 24 24 24 24 24 24 24 24 Missing 0 0 0 0 0 0 0 0 Mean 54.79 155.13 42.92 125.21 12.2750 5787.50 6941.67 7837.50 Median 54.50 155.50 42.00 130.00 12.3000 5500.00 6550.00 6850.00 Mode 54a 156 37a 120 12.30 4500 5100a 6000 Std. Deviation 7.132 4.205 12.068 22.864 1.28748 1514.082 2401.434 2900.946 Minimum 38 145 21 75 10.20 3400 4200 4500 Maximum 65 165 66 160 14.90 8700 14000 14500
a. Multiple modes exist. The smallest value is shown
OneWay
Test of Homogeneity of Variances
Levene Statistic df1 df2 Sig.
Leu.pre 1.781 2 21 .193
Leu.post1 5.511 2 21 .012
Leu.post2 8.882 2 21 .002
ANOVA
Sum of Squares df Mean Square F Sig.
Leu.pre Between Groups 17320000.000 2 8660000.000 5.136 .015 Within Groups 35406250.000 21 1686011.905 Total 52726250.000 23 Leu.post1 Between Groups 60525833.333 2 30262916.667 8.813 .002 Within Groups 72112500.000 21 3433928.571 Total 132638333.333 23 Leu.post2 Between Groups 102532500.000 2 51266250.000 11.828 .000 Within Groups 91023750.000 21 4334464.286 Total 193556250.000 23
Kruskall-Wallis Test Test Statisticsa,b
Leu.post1 Leu.post2
Chi-Square 12.152 11.310
Df 2 2
Asymp. Sig. .002 .004
a. Kruskal Wallis Test
b. Grouping Variable: Jenis.Obat
Post Hoc Tests
Multiple Comparisons
Dependent Variable: Leu.pre LSD
(I) Jenis.Obat (J) Jenis.Obat Mean Difference (I-J)
Std. Error Sig. 95% Confidence Interval Lower Bound Upper Bound
Propofol Pentothal -100.000 649.233 .879 -1450.15 1250.15 Etomidate 1750.000* 649.233 .014 399.85 3100.15 Pentothal Propofol 100.000 649.233 .879 -1250.15 1450.15 Etomidate 1850.000* 649.233 .010 499.85 3200.15 Etomidate Propofol -1750.000* 649.233 .014 -3100.15 -399.85 Pentothal -1850.000* 649.233 .010 -3200.15 -499.85
*. The mean difference is significant at the 0.05 level.
Mann Whitney Test – Propofol Pentothal Test Statisticsa
Leu.post1 Leu.post2
Mann-Whitney U 17.000 9.500
Wilcoxon W 53.000 45.500
Z -1.575 -2.365
Asymp. Sig. (2-tailed) .115 .018
Exact Sig. [2*(1-tailed Sig.)] .130b .015b a. Grouping Variable: Jenis.Obat
Mann-Whitney Test – Propofol Etomidate Test Statisticsa Leu.post1 Leu.post2 Mann-Whitney U 4.500 3.500 Wilcoxon W 40.500 39.500 Z -2.892 -2.998
Asymp. Sig. (2-tailed) .004 .003
Exact Sig. [2*(1-tailed Sig.)] .002b .001b a. Grouping Variable: Jenis.Obat
b. Not corrected for ties.
Mann-Whitney Test – Pentothal Etomidate Test Statisticsa
Leu.post1 Leu.post2
Mann-Whitney U 5.500 17.500
Wilcoxon W 41.500 53.500
Z -2.787 -1.525
Asymp. Sig. (2-tailed) .005 .127
Exact Sig. [2*(1-tailed Sig.)] .003b .130b a. Grouping Variable: Jenis.Obat
b. Not corrected for ties.
Repeated ANOVA – Propofol
Multivariate Tests
Value F Hypothesis df Error df Sig.
Pillai's trace .781 10.707a 2.000 6.000 .010
Wilks' lambda .219 10.707a 2.000 6.000 .010
Hotelling's trace 3.569 10.707a 2.000 6.000 .010
Roy's largest root 3.569 10.707a 2.000 6.000 .010
Each F tests the multivariate effect of waktu. These tests are based on the linearly independent pairwise comparisons among the estimated marginal means.
Pairwise Comparisons
Measure: MEASURE_1
(I) waktu (J) waktu Mean Difference (I-J)
Std. Error Sig.b 95% Confidence Interval for Differenceb
Lower Bound Upper Bound
1 2 -2587.500* 950.646 .030 -4835.420 -339.580 3 -4350.000* 1037.339 .004 -6802.916 -1897.084 2 1 2587.500 * 950.646 .030 339.580 4835.420 3 -1762.500* 422.551 .004 -2761.674 -763.326 3 1 4350.000* 1037.339 .004 1897.084 6802.916 2 1762.500* 422.551 .004 763.326 2761.674
Based on estimated marginal means
*. The mean difference is significant at the .05 level.
b. Adjustment for multiple comparisons: Least Significant Difference (equivalent to no adjustments).
Repeated ANOVA – Pentothal
Multivariate Tests
Value F Hypothesis df Error df Sig.
Pillai's trace .677 6.288a 2.000 6.000 .034
Wilks' lambda .323 6.288a 2.000 6.000 .034
Hotelling's trace 2.096 6.288a 2.000 6.000 .034
Roy's largest root 2.096 6.288a 2.000 6.000 .034
Each F tests the multivariate effect of waktu. These tests are based on the linearly independent pairwise comparisons among the estimated marginal means.
a. Exact statistic
Pairwise Comparisons
Measure: MEASURE_1
(I) waktu (J) waktu Mean Difference (I-J)
Std. Error Sig.b 95% Confidence Interval for Differenceb
Lower Bound Upper Bound
1 2 -425.000* 137.256 .017 -749.560 -100.440 3 -537.500 516.837 .333 -1759.625 684.625 2 1 425.000 * 137.256 .017 100.440 749.560 3 -112.500 417.663 .795 -1100.115 875.115 3 1 537.500 516.837 .333 -684.625 1759.625 2 112.500 417.663 .795 -875.115 1100.115
Based on estimated marginal means
*. The mean difference is significant at the .05 level.
b. Adjustment for multiple comparisons: Least Significant Difference (equivalent to no adjustments).
Repeated ANOVA – Etomidate
Multivariate Tests
Value F Hypothesis df Error df Sig.
Pillai's trace .845 16.408a 2.000 6.000 .004
Wilks' lambda .155 16.408a 2.000 6.000 .004
Hotelling's trace 5.469 16.408a 2.000 6.000 .004
Roy's largest root 5.469 16.408a 2.000 6.000 .004
Each F tests the multivariate effect of waktu. These tests are based on the linearly independent pairwise comparisons among the estimated marginal means.
a. Exact statistic
Pairwise Comparisons
Measure: MEASURE_1
(I) waktu (J) waktu Mean Difference (I-J)
Std. Error Sig.b 95% Confidence Interval for Differenceb
Lower Bound Upper Bound
1 2 -450.000* 94.491 .002 -673.436 -226.564 3 -1262.500* 279.628 .003 -1923.716 -601.284 2 1 450.000 * 94.491 .002 226.564 673.436 3 -812.500* 283.749 .024 -1483.459 -141.541 3 1 1262.500* 279.628 .003 601.284 1923.716 2 812.500* 283.749 .024 141.541 1483.459
Based on estimated marginal means
*. The mean difference is significant at the .05 level.
Lampiran . Biodata Mahasiswa
Identitas
Nama : Darlingga Panji Setyo
NIM : G2A008044
Tempat/tanggal lahir : Cirebon, 25 Februari 1990 Jenis kelamin : Laki - laki
Alamat : Jl. Ketilang D.XIV No.152 Perumnas Cirebon Nomor Telepon : 085724069000
Email : darlingga_ps@yahoo.com
Riwayat Pendidikan Formal
1. SD Negeri Ketilang Lulus tahun : 2002 2. SMP Negeri 1 Cirebon Lulus tahun : 2005 3. SMA Negeri 1 Cirebon Lulus tahun : 2008 4. FK UNDIP Masuk tahun : 2008
Keanggotaan Organisasi
1. Staf Bidang Kaderisasi BEM KU 2009 (2009 – 2010) 2. Staf Bidang Finansial ROHIS KU 2009 (2009 – 2010) 3. Staf Komisi Ahli BEM KU 2010 (2010 – 2011)